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angiogenesis occurs in the process of wound healing, 
and in a number of disease states, including cancer.
A number of proteins are known to activate en-
dothelial cell growth and movement. These include 
vascular endothelial growth factor (v e g f ), acidic and 
basic fibroblast growth factors, angiogenin, epidermal 
growth factor, scatter factor, placental growth factor, 
interleukin-8, and tumour necrosis factor α 3. Known 
naturally occurring inhibitors of angiogenesis include 
angiostatin, endostatin, interferons, platelet factor 4, 
thrombospondin, transforming growth factor β, 16-kDa 
fragment of prolactin, and tissue inhibitor of metal-
loproteinase-1, -2, and -3 3. In addition, the processes 
of both angiogenesis and metastasis require matrix 
metalloproteinases—enzymes that break down the 
surrounding tissue (the extracellular matrix) during 
blood vessel growth and tumour invasion.
At a critical point in the growth of a tumour, 
when the “angiogenic switch” is flipped to shift the 
tumour microenvironment to a pro-angiogenic state, 
the tumour sends out signals to the nearby endothelial 
cells to activate new blood vessel growth 3. The v e g f  
family of growth factors and its receptors constitute 
the most important signalling pathways in tumour 
angiogenesis 4. Angiogenesis is also related to me-
tastasis, assisting in the spread of a tumour to various 
parts of the body. It is generally true that tumours 
with higher densities of blood vessels are more likely 
to spread and to have poorer clinical outcomes. The 
shedding of large numbers of tumour cells from the 
primary tumour may not begin until after the tumour 
has a network of blood vessels.
2.  TARGETS AND AGENTS
The possibility of inhibiting angiogenesis as a potential 
therapeutic intervention in cancer treatment was first 
proposed by Folkman 5. A number of anti-angiogenic 
drugs are now either licensed or in clinical trials 
(Table i). In general, four strategies are being used by 
investigators to design anti-angiogenesis agents 2:
Blocking the ability of the endothelial cells to  • 
break down the surrounding matrix
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1.  INTRODUCTION
An exciting new area in cancer research and treatment 
involves the study of a class of agents called angio-
genesis inhibitors. These agents block the process of 
angiogenesis—the development of new blood ves-
sels. Angiogenesis is one of the hallmark features that 
tumours require for both growth and metastasis 1. For 
a tumour to grow beyond 1–2 mm in size, it needs to 
induce the formation of new blood vessels to supply 
its nutritional and other needs 2. This is the process that 
anti-angiogenic agents target. Cutting off the supply of 
nutrients and oxygen to a tumour will prevent its con-
tinued growth and spread to other parts of the body.
In most situations, endothelial cells lie dormant. 
But when needed, short bursts of blood vessel growth 
occur in localized parts of tissues. New vessel growth 
is tightly controlled by a finely tuned balance between 
factors that activate endothelial cell growth and those 
that inhibit it. In an adult, physiologic angiogenesis 
occurs in the ovaries, uterus, and placenta. Pathologic 
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Inhibiting normal endothelial cells directly • 
Blocking factors that stimulate angiogenesis • 
Blocking the action of integrin, a molecule on the  • 
endothelial cell surface
2.1  Results of Clinical Trials to Date
All currently approved anti-angiogenic drugs 
(Figure 1) block either v e g f  or v e g f  tyrosine kinase 
receptors (v e g f r s). These agents have been used 
either as single agents or in combination with 
conventional chemotherapeutic regimens. To date, 
the survival benefits of anti-angiogenic agents 
have been modest, but this modest success has 
led to interest in developing more effective ways 
to combine these agents with standard cytotoxic 
chemotherapies and with other agents targeting 
specific signalling pathways in tumour cells.
t a b l e  i  Anti-angiogenic agents
Target Agent Description
v e g f  ligand Bevacizumab (Avastina) Humanized anti-v e g f a  monoclonal antibody
Aflibercept (v e g f  Trapb) Fusion protein of v e g f r -1, v e g f r -2, and
   immunoglobulin G1 Fc fragment
v e g f  receptor
Extracellular domain IMC-1121B Human anti–v e g f r -2 monoclonal antibody
Cytoplasmic domain AEE788 v e g f r -2 and e g f r  inhibitor
Axitinib (AG-013736) v e g f r -1,2 and p d g f r  inhibitor
BMS-582664 v e g f r -2 and f g f r inhibitor
Motesanib (AMG-706) v e g f r -1,2,3; p d g f r b ; and c-Kit inhibitor
OSI-930 v e g f r -2 and c-Kit inhibitor
Pazopanib (GW-786034) v e g f r -2 inhibitor
Tandutinib (MLN-518) Flt-3, p d g f r , c-Kit inhibitor
Vatalanib (PTK787) v e g f r -1,2,3 and p d g f r b  inhibitor
Sorafenib (BAY 43–9006) b-Raf; v e g f r -2,3; p d g f r b ; Flt-3; and c-Kit inhibitor
Sunitinib (SU11248) v e g f r -1,2; p d g f r a , p d g f r b ; and c-Kit inhibitor
Cediranib (AZD2171) v e g f r -1,2,3; p d g f r b ; and c-Kit inhibitor
Vandetanib (ZD6474) v e g f r -2,3 and e g f r  inhibitor
XL-184 v e g f r -2, Met, c-Kit, Flt-3, and Tie2 inhibitor
XL-999 v e g f r -1,2,3; f g f r; p d g f r ; and Flt-3 inhibitor
Endogenous inhibitors Angiostatin Cleavage fragment of plasminogen
Endostatin Cleavage fragment of collagen x v i i i
Thrombospondin 1 Extracellular glycoprotein
Other EMD 121974 (Cilengitidec) αvβ3 Integrin receptor inhibitor
ATN-161 αvβ1 Integrin receptor inhibitor
Volociximab αvβ1 Integrin receptor inhibitor
Vitaxin Human monoclonal antibody to αvβ3 integrin receptor
AMG-386 Angiopoietin inhibitor
Thalidomide Immunomodulatory agent
AGN-745/SIRNA027 sir n a  inhibiting v e g f r -1 mr n a
a  Genentech, San Francisco, CA, U.S.A.
b  Regeneron, Tarrytown, NY, U.S.A.
c  Merck and Co., Whitehouse Station, NJ, U.S.A.
v e g f  = vascular endothelial growth factor; v e g f r  = vascular endothelial growth factor receptor; e g f r  = epidermal growth factor receptor; 
p d g f r [a,b] = platelet-derived growth factor receptor [α, β]; f g f r = fibroblast growth factor receptor.HIRTE
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Single-agent activity has been demonstrated 
with sunitinib, which inhibits the v e g f r  tyrosine 
kinase in advanced renal cancer 6, and sorafenib, 
which inhibits the v e g f r  tyrosine kinase and also 
has Raf kinase inhibitory activity in renal cancer and 
hepatoma 7,8. Bevacizumab, the first anti-angiogenic 
agent approved by the U.S. Food and Drug Admin-
istration, significantly increased overall survival or 
progression-free survival in patients with metastatic 
colorectal cancer, non-small-cell lung cancer, and 
breast cancer when given in combination with con-
ventional chemotherapeutic agents 9–11.
Inhibiting the messenger r n a  (mr n a ) for either 
angiogenic growth factors or their receptors is another 
approach that could be used to inhibit factors that 
stimulate angiogenesis. Although no such agents have 
yet been tested in the cancer setting, one such agent, 
AGN-027, which is a small interfering r n a  (sir n a ) 
directed against v e g f r -1 mr n a , has shown promise 
in ocular neovascularization and may be promising 
in the oncology setting 12.
Some of the differences between standard che-
motherapy and anti-angiogenesis therapy result from 
the targeting by angiogenesis inhibitors of dividing 
endothelial cells rather than tumour cells. Anti-angio-
genic drugs are not as likely to cause symptoms such as 
bone marrow suppression, gastrointestinal symptoms, 
or hair loss, which are characteristic of standard che-
motherapy treatments. Also, because anti-angiogenic 
drugs may not necessarily kill tumours, but rather hold 
them in check indefinitely, the endpoint of early clini-
cal trials may be different from those used in standard 
therapies. Rather than look for tumour response only, 
an evaluation of increases in survival or time to disease 
progression may be appropriate.
2.2  Toxicities
Anti-v e g f  therapy can lead to specific—and some-
times unexpected—toxicities such as hypertension, 
proteinuria, bowel perforation, hemorrhage, and 
arteriothrombotic events. It is thought that the hyper-
tension associated with anti-v e g f  therapy is a result 
of inhibition of endothelial cell–derived nitric oxide, 
which is a pathway known to be mediated by v e g f r 2 
activation. However, the basis of other toxicities, such 
as bowel perforation, remains unclear 13.
Agents such as bevacizumab or aflibercept have 
exquisite specificity for their target (v e g f); agents 
such as sorafenib and sunitinib, which block the 
intracellular tyrosine kinase domain of the v e g f  
receptor, have a broader spectrum of activity and 
inhibitory effects on a number of receptors such as 
platelet-derived growth factor receptor and c-Kit in 
addition to v e g f r . Broader specificity may be im-
portant in preventing the development of resistance 
to inhibition of angiogenesis; however, broader 
specificity is also associated with a broader range 
f i g u r e  1 A number of agents have been developed that target the vascular endothelial growth factor (V e g f) pathway. These include antibod-
ies and soluble receptors that specifically bind to V e g f, antibodies that prevent V e g f receptor (V e g f r) activation, small-molecule inhibitors 
that block the tyrosine kinase activity of the intracellular domain of the V e g f receptor, and small interfering r n as (sir n as) that inhibit the 
messenger r n a for V e g f r.ANGIOGENESIS INHIBITION THERAPY
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of potential toxicities such as fatigue and skin and 
gastrointestinal toxicities 14.
2.3  Mechanisms of Resistance
Drug resistance is a major problem with chemo-
therapy agents. Most cancer cells are genetically 
unstable, more prone to mutations, and therefore 
likely to produce drug-resistant cells. Because anti-
angiogenic drugs target normal endothelial cells, 
which are genetically stable, it was initially hoped 
that resistance to these agents might not develop. 
However, despite major advances in the clinical de-
velopment of v e g f -targeted therapy, tumours in most 
patients are inherently resistant. When a response is 
obtained, the benefit of v e g f  inhibitors is transient, 
generally lasting only weeks to months. Therefore, 
nearly all tumours are either inherently resistant or 
develop acquired resistance to agents targeting the 
v e g f /v e g f r  pathway 15.
The emergent mechanisms of resistance include 
revascularization because of upregulation of alterna-
tive pro-angiogenic signals; protection of the tumour 
vasculature by recruitment of pro-angiogenic inflam-
matory cells or by an increase in protective pericyte 
coverage; accentuated invasiveness of tumour cells 
into local tissue to co-opt normal vasculature; and 
increased metastatic seeding and tumour cell growth 
in lymph nodes and distant organs 16.
2.4  Combinations with Standard Therapy or Other 
Targeted Agents
Anti-angiogenesis therapy may prove useful in 
combination with therapy directly aimed at tumour 
cells. Because each therapy is aimed at a different 
cellular target, the hope is that the combination will 
prove more effective. Because anti-angiogenics 
are generally cytostatic rather than cytoreductive, 
combinations involving conventional cytotoxic 
chemotherapies may be useful for maximizing 
therapeutic activity.
A number of hypotheses have been proposed with 
respect to the mechanistic basis by which anti-an-
giogenic drugs enhance the effects of chemotherapy. 
Anti-angiogenics targeting the v e g f  pathway reduce 
the hyperpermeable nature of the tumour vasculature 
such that a transient reduction will occur in the high 
tumour interstitial fluid pressures. In addition, the 
chaotic and dysfunctional tumour-associated vascula-
ture can be transiently normalized, allowing for better 
delivery of chemotherapeutic agents to the tumour 
environment. This transient “window” of vascular 
normalization and decrease in interstitial pressure 
may allow for an increase in the concentration of 
chemotherapy agents delivered to the tumour 17.
By understanding the pathways that become 
upregulated during the development of resistance 
to anti-angiogenics, it may possible to combine 
anti-v e g f  inhibition strategies with approaches that 
inhibit these resistance pathways to achieve more 
effective inhibition of angiogenesis 15.
2.5  Surrogate Markers of Anti-angiogenic Activity
An ideal surrogate marker could be used to guide the 
clinical development of the anti-angiogenics and to 
select the patients most likely to benefit from this ap-
proach. A number of such potential surrogate markers 
have been assessed, including circulating proteins 
(v e g f  or other pro-angiogenic growth factors), soluble 
v e g f r , and various adhesion molecules associated 
with vascular endothelial cells that can be released 
into the circulation 15. Measuring the number of cir-
culating cells thought to be relevant to angiogenesis, 
including circulating endothelial cells and circulating 
endothelial progenitor cells, is also a possibility 18. 
Noninvasive imaging by dynamic contrast-enhanced 
magnetic resonance, computed tomography, or high-
frequency ultrasound can also be used to assess blood 
flow or vascular permeability 18. Thus far, however, 
none of these approaches has been validated in the 
clinical setting.
3.  SUMMARY
Angiogenesis is a process crucial to the growth and 
metastasis of cancer. Agents such as inhibitors of 
the v e g f  pathway have shown promising activity 
as single agents and in combination with standard 
chemotherapy agents. However, inherent or acquired 
resistance to these agents eventually develops. Un-
derstanding these mechanisms of resistance and 
validating surrogate makers of anti-angiogenic 
activity will be key to developing more effective 
anti-angiogenic therapies in the future.
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